| (Values in U.S. Thousands) | Mar, 2020 | Mar, 2019 | Mar, 2018 | Mar, 2017 | Sep, 2017 |
| Sales | 0 | 0 | 0 | 0 | -8,520 |
| Sales Growth | unch | unch | unch | +100.00% | -136.01% |
| Net Income | -146,750 | -111,350 | -37,070 | -26,970 | 5,030 |
| Net Income Growth | -31.79% | -200.38% | -37.45% | -636.18% | +16,666.67% |
Urovant Sciences Ltd (UROV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom.
Fiscal Year End Date: 03/31